FibroGen to Report Third Quarter 2025 Financial Results
Rhea-AI Summary
FibroGen (NASDAQ: FGEN) will report its third quarter 2025 financial results on Monday, November 10, 2025 after market close. Management will host a conference call and live webcast the same day at 5:00 PM Eastern Time to discuss the results, provide a business update, and conduct a live Q&A session.
Investors can access a live audio webcast or register for phone dial-in details. A replay of the webcast will be available for a limited time on the company’s Events & Presentations page.
Positive
- None.
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, FGEN declined 0.09%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
SAN FRANCISCO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce third quarter 2025 financial results on Monday, November 10 after market close. FibroGen will also conduct a conference call on that day at 5:00 PM Eastern Time with the investment community to further detail the company's corporate and financial performance.
Conference Call and Webcast Presentation
The FibroGen management team will host a conference call and webcast presentation to discuss the financial results and provide a business update. A live Q&A session will follow the brief presentation. Interested parties may access a live audio webcast of the conference call here. To access the call by phone, please register here, and you will be provided with dial in details. A replay of the webcast will also be available for a limited time on the Events & Presentations page on FibroGen’s website.
About FibroGen
FibroGen, Inc. is a biopharmaceutical company focused on development of novel therapies at the frontiers of cancer biology and anemia. Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. The Company continues to evaluate the development plan for the Phase 3 trial of roxadustat in anemia associated with lower-risk myelodysplastic syndrome (LR-MDS) in the U.S. FG-3246 (also known as FOR46), a first-in-class antibody-drug conjugate (ADC) targeting CD46, is in Phase 2 development for the treatment of metastatic castration-resistant prostate cancer. This program also includes the development of FG-3180, an associated CD46-targeted PET biomarker. For more information, please visit www.fibrogen.com.
For Investor Inquiries:
David DeLucia, CFA
Senior Vice President and Chief Financial Officer
ir@fibrogen.com
FAQ
When will FibroGen (FGEN) release its Q3 2025 earnings?
What time is the FibroGen (FGEN) Q3 2025 conference call and webcast?
How can investors join the FibroGen (FGEN) earnings webcast on November 10, 2025?
Will FibroGen (FGEN) provide a Q&A during the November 10, 2025 presentation?
Will a replay of the FibroGen (FGEN) November 10, 2025 webcast be available?
